

# S2408 Kick-Off Meeting

## S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

**THURSDAY, MAY 1 • 5:30 – 6:30 PM PT • SEACLIFF CD (BAY LEVEL)**

S2408 is evaluating whether a single dose of the somatostatin analogue *lanreotide* may prevent the “Achilles Heel” of pancreatic surgery – postoperative pancreatic fistula (POPF) – in patients undergoing distal pancreatectomy for cancer or a pre-malignant pancreatic lesion.

POPF delays chemotherapy, increases healthcare costs, and decreases survival times.

### STUDY CHAIR



Jonathan Sham, MD, MBEE

### STUDY CO-CHAIR



Venu Pillarisetty, MD

### SPONSORING COMMITTEE CHAIR



Robert Krouse, MD

### LEAD BIOSTATISTICIANS




Katherine Guthrie, PhD



Kathryn Arnold, MS

### PATIENT ADVOCATE



Valerie Fraser

**BIostatistician:** Amy Darke, MS • **DATA COORDINATOR:** Roxanne Topacio, CCRP • **DATA COORDINATOR:** Kim Carvalho  
**ORP LIAISON:** Shirley Siu • **PROTOCOL PROJECT MANAGER:** Andrea Garcia

### The S2408 kick-off meeting will provide:

- An overview of the study design of this newly activated phase III multicenter trial
- Considerations for site feasibility assessments and local activation
- An opportunity for interactive discussion with the study team

### INCLUDING KEY INFORMATION ABOUT



Eligibility



Single-dose treatment



Surveillance



Blinding procedures



Specimen collection



Patient-reported outcomes

**SURGEONS, MEDICAL ONCOLOGISTS, AND ONCOLOGY RESEARCH PROFESSIONALS ARE ENCOURAGED TO ATTEND!**

**Hybrid session:** IN-PERSON & VIRTUAL attendance options

S2408 activated on 2/14/2025. All study documents are now accessible via [CTSU.org](https://www.ctsu.org).